Amgen, US0311621009

Amgen stock: Piper Sandler raises target to 542 dollars

Published on 11/21/2026 at 11:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen stock gained a fresh Piper Sandler target after a post-third-quarter review. The analyst highlighted pipeline and label-expansion opportunities.

Analyst focus shifts to pipeline

  • Piper Sandler retained its Overweight rating on Amgen.
  • The revised view centers on dazodalibep and Imdelltra as potential growth drivers.
  • Pipeline depth and label expansion remain key factors in the analyst assessment.
Amgen, US0311621009, Illustration mit AI erstellt.

Piper Sandler raised its price target for Amgen on November 19, 2026, while retaining an Overweight rating. The move adds a fresh analyst view to the biotechnology group's pipeline prospects.

According to Markets Insider, Piper Sandler's post-third-quarter model reflects potential contributions from dazodalibep in patients with moderate-to-severe systemic Sjogren's disease and from Imdelltra as maintenance therapy in first-line extensive-stage small-cell lung cancer.

Pipeline remains central to valuation

Piper Sandler said the two opportunities could support further value creation. The firm also pointed to additional pipeline and label-expansion opportunities as potential support for a higher valuation multiple, while expecting the base business to continue generating growth ahead of future loss-of-exclusivity exposure.

The analyst action gives investors a more constructive view of Amgen's development portfolio, but the commercial contribution of the cited programs still depends on regulatory, clinical and market execution. The revised target therefore places continued attention on the conversion of pipeline progress into product growth.

Amgen company facts

  • Company: Amgen Inc.
  • ISIN: US0311621009
  • Home listing: Nasdaq
  • Ticker: AMGN
  • Xetra symbol: AMG.DE

Broader market developments can be followed in Current market reports.

More news and analyses on Amgen stock

Disclaimer...
en | US0311621009 | AMGEN | boerse | 70541884 | bgmi